COMPASS Pathways establishes The Centre for Mental Health Research and Innovation with King's College London and SLaM

COMPASS Pathways plc

Up to £12M investment over 10-year term; Centre to accelerate psychedelic therapy research and new care models.
Initial focus on COMP360 psilocybin therapy for TRD, PTSD, and anorexia nervosa; expects 650-700 patients over 5 years.
Facilities to be built at Bethlem Royal Hospital in London; state-of-the-art clinical trial space.
Partnership with UK's largest NHS mental health trust (SLaM) and King's College London's IoPPN.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.